Clinical Trials Logo
  1. Home
  2. Malignancy
  3. NCT05761366
  4. Details
NCT05761366 Clinical Trial

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Malignancy Clinical Trial

Official title:
Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05761366
Other study ID # NCC3688
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 13, 2022
Est. completion date October 13, 2025

Study information
Verified date March 2024
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Xin Cheng, MD
Phone 15120002998
Email cxpumc@foxmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.

Description:

Al18F-PSMA-BCH PET/CT will be performed on patients with suspected or clearly diagnosed PSMA positive-expressing tumors (including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.) , to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.

Recruitment information / eligibility
Status Recruiting
Enrollment 400
Est. completion date October 13, 2025
Est. primary completion date October 13, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with suspected or clearly diagnosed PSMA positive-expressing tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc. 2. Age is 18 or older; No gender limitation. 3. Signed the informed consent. 4. Willing and able to cooperate with all projects in this study. Exclusion Criteria: 1. Patients with serious neurological diseases,or gastrointestinal tract disease, cardiovascular disease, liver disease, kidney disease, blood system disease, endocrine system disease, respiratory system disease, immune deficiency disease, etc 2. Claustrophobia. 3. Pregnant or lactation women. 4. Received experimental drug or device within 1 month.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Al18F-PSMA-BCH PET/CT
Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.

Locations
Country Name City State
China National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College Beijing Chaoyang

Sponsors (1)
Lead Sponsor Collaborator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Diagnostic value Sensitivity and Specificity of 18F-PSMA PET / CT for the diagnosis of Prostate Specific Membrane Antigen Positive Tumor through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05640115 - Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent Early Phase 1
Recruiting NCT02891642 - Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
Completed NCT02282449 - Power Injectable Versus a Non-Power Injectable, Upper Arm, TIVAD for Chemotherapy N/A
Completed NCT01212731 - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Completed NCT01199822 - Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors Phase 1
Recruiting NCT04122469 - The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease N/A
Recruiting NCT03561727 - Risk Factors for Development of Incisional Hernia in Transverse Incisions N/A
Terminated NCT03251924 - A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03997968 - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT00092222 - Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Phase 2
Recruiting NCT05770102 - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2/Phase 3
Recruiting NCT05886764 - Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials N/A
Not yet recruiting NCT05992363 - Tandem Polyurethane Stents Compared to Single Silicone Stent for Malignant Ureteral Obstruction Phase 3
Recruiting NCT04887545 - Immune- and Microenvironment- Proteogenomics Profiling for Classifying Lung Cancer Patients
Completed NCT03061955 - Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)
Completed NCT03909464 - Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy
Active, not recruiting NCT02649491 - Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy N/A
Recruiting NCT02776995 - Tumor Monitoring Using Thermography During Radiation Therapy N/A
Active, not recruiting NCT01242072 - Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Phase 1
Completed NCT00924937 - CORonary Diet Intervention With Olive Oil and Cardiovascular PREVention N/A